Tandem Diabetes Care announces the commercial launch of the Tandem Mobi insulin delivery system in the United States.
Tandem Mobi is said to be the world’s smallest automated insulin administration system for diabetics.
Tandem has begun accepting orders for the system and is shipping the product to eligible customers nationwide.
Tandem Mobi represents a new approach to diabetes management, leveraging the company’s Control-IQ technology.
This Control-IQ hybrid closed-loop system is approved for use by patients with type 1 diabetes who are 6 years of age and older.
Several clinical trials and real-world studies have shown that this system reduces flight time both day and night.
Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.
Company Profile – Free Sample
You will receive a download email shortly
We are confident in the unique quality of our company profile. However, we want you to make the decision that is most beneficial for your business, so we are offering free samples that you can download by submitting the form below.
by global data
The Tandem Mobi system is less than half the size of the insulin pump t:slim X2.
Users can wear the device on their body using a lightweight adhesive sleeve, clip it to their clothing, or simply slip it into their pocket.
The system is compatible with all existing Tandem branded infusion sets manufactured by Convatec, including the new 5-inch tube option exclusive to Tandem Mobi.
These infusion sets offer the ability for users to temporarily disconnect for convenience and offer over 30 combinations of injection sites and tubing lengths.
The Tandem Mobi mobile app gives you full control of iOS through your compatible iPhone.
In terms of sensor compatibility, it will work with the DexCom G6 continuous glucose monitoring (CGM) system and will be integrated with the Dexcom G7 in the second quarter of 2024, and later with the Abbott FreeStyle Libre 3 sensor.
The Tandem Mobi is said to be water-resistant and features flexible pump controls with a physical button to deliver insulin boluses without the need for an iPhone. It also incorporates advanced technologies such as wireless charging and remote software update capabilities.
said John Sheridan, President and CEO of Tandem Diabetes Care. “This small, wearable pump has exceeded user expectations from our early access program, and we are excited to bring this exciting new technology to more people in the diabetes community.”
“With this launch, we are executing on our strategy to deliver a differentiated portfolio of durable insulin pumps, offering new options for choice and wearability.”
Last year, Tandem launched the latest version of its t:slim X2 insulin pump software in the U.S., which integrates with the DexCom G7 CGM system.
